JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

Home・Aandelen Lijst・Eli Lilly and Co.

Eli Lilly and Co.

Gesloten

SectorGezondheidszorg

1,066.82 2.48

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1064.22

Max

1070.02

Belangrijke statistieken
By Trading Economics
Inkomsten	758M 7.4B
Verkoop	507M 20B
K/W Sectorgemiddelde	35.088 49.701
EPS	8.55
Dividendrendement	0.62
Winstmarge	37.355
Werknemers	50,000
EBITDA	971M 9.4B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+18.99% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	0.62% 2.39%
Volgende Winsten	5 aug 2026
Volgende dividenddatum	10 jun 2026
Volgende Ex Dividend datum	14 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	105B 881B
Vorige openingsprijs	1064.34
Vorige sluitingsprijs	1066.82

Nieuwssentiment

By Acuity

21%

79%

31 / 345 Rangschikking in Healthcare

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2026, 14:24 UTC

Acquisities, Fusies, Overnames

Eli Lilly Buys Engage Biologics for Up to $202 Million

30 apr 2026, 12:01 UTC

Winsten

Belangrijke Marktbewegers

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

20 mei 2026, 13:35 UTC

Acquisities, Fusies, Overnames

Engage Bio: Eli Lilly Deal Includes Upfront, Milestone Payments >LLY

20 mei 2026, 13:34 UTC

Acquisities, Fusies, Overnames

Engage Bio Acquired by Eli Lilly for Up to $202 Million >LLY

7 mei 2026, 09:30 UTC

Winsten

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mei 2026, 12:36 UTC

Winsten

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mei 2026, 10:12 UTC

Winsten

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mei 2026, 09:58 UTC

Winsten

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30 apr 2026, 20:59 UTC

Populaire aandelen

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 apr 2026, 20:12 UTC

Winsten

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 16:43 UTC

Winsten

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 apr 2026, 16:10 UTC

Marktinformatie

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 apr 2026, 15:13 UTC

Winsten

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 14:58 UTC

Winsten

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 apr 2026, 14:53 UTC

Winsten

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 apr 2026, 14:50 UTC

Winsten

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 apr 2026, 14:42 UTC

Winsten

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 apr 2026, 14:39 UTC

Winsten

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 apr 2026, 14:35 UTC

Winsten

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 apr 2026, 14:24 UTC

Winsten

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 apr 2026, 14:17 UTC

Winsten

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 apr 2026, 13:56 UTC

Winsten

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 13:37 UTC

Populaire aandelen

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 apr 2026, 12:32 UTC

Marktinformatie

Winsten

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30 apr 2026, 12:29 UTC

Marktinformatie

Winsten

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30 apr 2026, 12:23 UTC

Marktinformatie

Winsten

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30 apr 2026, 12:10 UTC

Winsten

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 12:08 UTC

Winsten

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30 apr 2026, 12:04 UTC

Marktinformatie

Winsten

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30 apr 2026, 11:39 UTC

Populaire aandelen

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

18.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,267.24 USD 18.99%

Hoogste 1,500 USD

Laagste 850 USD

Gebaseerd op 23 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

23 ratings

Buy

Hold

Sell

Gebaseerd op 23 analisten die aandelenratings hebben gegeven aan Eli Lilly and Co. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

31 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.